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Abstract A specific inhibitor of protein tyrosine phosphatase 
(PTPase), RK-682 (3-bexadecanoyl-5-hydroxymethyl-tetronic 
acid) was isolated from microbial metabolites. In vitro, RK-682 
inhibited dephosphorylation activity of CD45 and VHR with ICso 
54 and 2.0 pM, respectively. In situ, sodium orthovanadate and 
RK-682 enhanced the phosphotyrosine l vel of Ball-1 cells, a 
human B cell leukemia, but not the phosphoserinelthreonine l vel. 
The PTPase inhibitors, however, had the different arrest point on 
the cell cycle progression. Sodium orthovanadate inhibited the 
cell cycle progression at G2/M boundary phase, on the other hand, 
RK-682 inhibited the GJS transition. 
Key words: Tyrosine phosphatase inhibitor; Cell cycle; cdc25B; 
CD45; VHR; Microbial product 
I. Introduction 
Reversible phosphorylation on tyrosine residues of proteins 
is one of the earliest and important events in the signal 
transduction pathways leading to the stimulation of cell prolif- 
eration. Because many oncogenes encode protein tyrosine ki- 
nases (PTKs), much attention had been paid to PTK compared 
with protein tyrosine phosphatases (PTPases). Recently, it was 
reported that PTPase played an important role in the signal 
transduction [1]. Mitosis is initiated following the activation of 
cdc2-cyclin B kinase complex, so-called M-phase promoting 
factor or maturation promoting factor (MPF) [2]. The key step 
in the activation of MPF is dephosphorylation Thr-14 and 
Tyr-15 of cdc2 protein by cdc25, a kind of dual-specificity 
protein phosphatases [3]. VHR (VHl-related human protein), 
which was isolated from a human fibroblast has the dual-spec- 
ificity phosphatase activity towards phosphotyrosine and 
phosphoserine/threonine like cdc25 [4]. 
The receptor-type PTPase, CD45 (a leukocyte common anti- 
gen) activates protein tyrosine kinase p56 Ick [5] and p59 ryn [6,7], 
which are associated with the intracellular domain of the T cell 
surface glycoproteins, CD4 and CD8. CD45 is involved in T 
cell [8] and B cell [9] development and activation. 
Specific PTPase inhibitors should be useful as a biological 
tool to reveal the signal transduction. Okadaic acid [10] and 
tautomycin [11], which are known to inhibit serine/threonine 
protein phosphatases (PPases), are valuable tools to test the 
physiological role of serine/threonine phosphorylation i the 
signal transduction. On the contrary, only a few PTPase inhib- 
itors, for example, sodium orthovanadate (vanadate), phenyl- 
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arsine oxide (PAO) [12] and dephostatin [13] have been 
known. A more potent and selective PTPase inhibitor is still 
required. 
To discover specific PTPase inhibitors, we have started the 
screening of microbial metabolites. In this paper, we describe 
the isolation of RK-682, 3-hexadecanoyl-5-hydroxymethyl- 
tetronic acid, as a potent PTPase inhibitor from the fermenta- 
tion of Streptomyces sp. 88-682 and elucidate the inhibitory 
activity of RK-682 to PTPases. 
2. Materials and methods 
2.1. Isolation of RK-682 
Streptomyces sp.88-682, isolated in Kuroishi City, Aomori, Japan, 
was cultured in 36 liters of a production medium (glucose 2.0%, soy 
bean meal 2.5%, soluble starch 1.0%, dry yeast 0.4%, meat extract 0.1%, 
NaCI 0.2% and K2HPO 4 0.005%) for 96 h at 28°C. The mycelial cake 
was collected from the fermentation broth and extracted with acetone. 
After removal of acetone, the residual solution was extracted with ethyl 
acetate under acidic condition. The extract was concentrated to dryness 
and applied to a silica gel (Kiesel gel 60, Merck; 8 diam. x 60 cm), which 
was eluted with a mixture of methanol/chloroform (1:9 to 2:8). The 
active fractions were collected and applied to a column (6 diam. x 80 
cm) of Sephadex LH-20 (Pharmacia) equilibrated with methanol. The 
eluted active fraction from Sephadex LH-20 was further purified by 
preparative HPLC using an ODS column (Capcell pak; 20 diam. x 250 
mm; Shiseido, Tokyo, Japan) with 40% tetrahydrofuran/water to yield 
700 mg of RK-682 (retention time; 14.1 min, flow rate; 6.0 ml/min). 
2.2. Cell culture 
A human B cell leukemia cell line, Ball-1 was obtained from Cell 
Bank, R IKEN and maintained in RPMI 1640 medium (Nissui Seiyaku, 
Tokyo, Japan) supplemented with 10% FCS; fetal calf serum (Gibco). 
A mouse hybridoma 1 G2 cell line was provided from ATCC (Rockville, 
MD, USA). 
2.3. Phosphatase assay 
GST-VHR fusion protein (VHR) was prepared as described [4]. The 
plasmid to express GST-cdc25B fusion protein (cdc25B) was con- 
structed by insertion of the AatI fragment (nucleic acids 1394-1844) of 
the human cdc25B cDNA [14] into the SmaI site of the pGEX1 vector. 
Dephosphorylation activity of VHR and cdc25B to p-nitrophenyl- 
phosphate (pNpp) was measured in the assay buffer (25 mM MOPS, 
pH 6.5, 5 mM EDTA, 1 mM dithiothreitol) [15]. A CD45 fraction was 
prepared from Balm cells by the method as described [16], and its 
PTPase activity to phosphotyrosine was measured by colorimetric 
assay [9]. 
2.4. lmmunoblotting 
Western blotting was performed as described below. Ball-1 cells 
(1 x 106) were treated with phosphatase inhibitors for 20 h at 37°C. The 
cell protein was subjected to 8% SDS-PAGE, electrophoretically trans- 
ferred to a nitrocellulose membrane, and incubated for 1 h with a 
monoclonal ntibody to phosphotyrosine (obtained from mouse hy- 
bridoma cells, 1G2) or phosphothreonine (Biomakor, Rehovot, Israel). 
The membrane was incubated with 0.5/tg/ml of horseradish peroxidase 
conjugated anti-mouse IgG (Kirkegaard & Perry Lab., Gaithersburg, 
MD, USA) and visualized with a chemiluminescence system (ECL, 
Amersham). 
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2.5. Cell cycle assay 
Ball-1 cells were cultured in a 12-well plate at a concentration of
2 x 105 cells/well in 1 ml of 10% FCS-RPMI1640 medium with inhib- 
itors at 37°C for 20 h. The cells were then washed with PBS (phosphate- 
buffered saline), stained with propidium iodide (Sigma) and analyzed 
by flow cytometry (Coulter, Epics Profile II, Hialeah, FL, USA). 
3. Results 
3.1. Identification and characterization of RK-682 
We have screened about 350 strains of soil actinomycetes for 
PTPase inhibitors and found that Streptomyces sp.88-682 pro- 
duced RK-682. The isolation of RK-682 was monitored by the 
inhibitory activity towards VHR (Table 1). The chemical struc- 
ture of RK-682 was identified as 3-hexadecanoyl-5-hydroxy- 
methyl tetronic acid (Fig. 1) by means of 2D-NMR and HR- 
FABMS. 
We investigated the inhibitory activity of RK-682 to CD45 
and VHR. RK-682 inhibited the dephosphorylation activity of 
CD45 to phosphotyrosine with ICs0 54 pM (Fig. 2A). RK-682 
was more potent han vanadate (ICs0 = 200 pM). On the other 
hand, okadaic acid and tautomycin had no detectable activity 
toward CD45. RK-682 and vanadate inhibited the 
dephosphorylation activity of VHR in vitro with ICs0 2.0 and 
16 aM, respectively (Fig. 2B). 
The inhibitory kinetics of RK-682 and vanadate against 
VHR substrate (pNpp) were measured and shown in the Line- 
weaver-Burk plot (Fig. 3A and B). Whereas RK-682 was a 
typical noncompetitive inhibitor with K~ of 2.5/.tM, vanadate 
was a competitive inhibitor with K~ of 36 pM. These results 
suggest that vanadate mimics a substrate, but RK-682 is not a 
pNpp mimetic compound. 
RK-682 was slightly soluble to MeOH, CHC13 and ethyl 
acetate, but hardly soluble to H20. When cells were incubated 
with 10 pM RK-682, incorporated RK-682 was not detectable 
within 5 h and reached only 10 pM (0.1% of total amount) after 
20 h (data not shown). The inhibitory concentration fRK-682 
in situ was much higher than that in vitro, because the mem- 
brane permeability of the inhibitor was poor. 
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Fig. 1. Structure of RK-682. 
3.2. Effect of RK-682 on the cellular phosphoprotein of Ball-I 
cells 
RK-682 inhibited dual-specificity protein phosphatase VHR 
activity. To determine the specificity of RK-682 in situ, we 
investigated the effect of the inhibitor on the phosphorylation 
state of cellular phosphoproteins in Ball-1 cells. Ball-1 cell ly- 
sates treated with phosphatase inhibitors were analyzed by 
Western blotting with anti-phosphotyrosine (Fig. 4B) or anti- 
phospbothreonine antibody (Fig. 4C). Okadaic acid (lanes 2 
and 3) did not increase the tyrosine phosphorylation level of 
any cellular phosphoprotein but markedly increased the thre- 
onine phosphorylation level. On the contrary, vanadate (lanes 
4 and 5) and RK-682 (lanes 6, 7 and 8) increased the only 
tyrosine phosphorylation level of proteins (approximately 110 
and 90 kDa). These results showed that RK-682 specifically 
inhibited PTPase, but not PPase. Moreover, RK-682 and vana- 
date might inhibit the different cellular tyrosine phosphatases, 
which caused the differential phosphorylation level of 60-kDa 
protein indicated by an arrow. 
3.3. Effect of RK-682 on the cell cycle progression 
VHR is a dual-specificity phosphatase like cdc25 which is a 
cell cycle regulating phosphatase. Therefore, we next investi- 
gated the effect of RK-682 on the cell cycle of Ball-1 cells. 
RK-682 had an inhibitory effect on the cell cycle progression 
at G~ phase (Fig. 5C). On the other hand, vanadate did not 
inhibit G~ phase but G2 phase (Fig. 5B). These results suggest 
that two PTPase inhibitors inhibit different phosphatases which 
regulate the cell cycle progression. 
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Fig. 2. The effect of phosphatase inhibitors to the dephosphorylation activity of CD45 and VHR. Inhibitory activity of okadaic acid (t), tautomycin 
(~,), vanadate (*) and RK-682 (I) to CD45 (A) and GST-VHR (B). Data are the average of three independent experiments. 
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Fig. 3. The Lineweaver-Burk plot of RK-682 (A) and vanadate (B) to pNpp. The concentrations of RK-682 were 2.7 ($), 4. I (©), 5.4 (-,) pM. VHR 
(20/.tg/ml) hydrolyzed pNpp (I, 2, 3, 4, 5 mM). Vanadate concentrations were 0 (o), 0.16 (©), 0.25 (-,) raM. 
3.4. Effect of PTPase inhibitors on cdc25B in vitro 
We investigated the inhibitory activity of vanadate and 
RK-682 against he bacterially expressed cdc25B phosphatase 
(Fig. 6), which regulated G2/M progression by dephosphoryla- 
tion of MPF. Vanadate inhibited the phosphatase activity of 
cdc25B in vitro (ICs0 = 30/.tM) but RK-682 did not. The spec- 
ificity of RK-682 to PTPases was different from that of vana- 
date, and they showed different arrest points of the cell cycle. 
4. Discussion 
Recently, it was reported that tyrosine phosphatases 
(PTPases) and dual-specificity phosphatases were key enzymes 
in the signal transduction pathway for a wide range of cellular 
processes [17]. Dual-specificity phosphatases, for example, 
cdc25, HVH1 and 3CH134 are known to be involved in cell 
cycle progression [3], MAP kinase inactivation [18] and growth 
factor stimulation [19], respectively. The specific inhibitor of 
the dual-specificity phosphatase will be a valuable tool to reveal 
the signal transduction. The bacterially expressed VHR had 
stronger dephosphorylation activity to pNpp compared with 
the bacterially expressed cdc25B in vitro. Therefore, we used 
VHR for the screening of inhibitors from microbial metab- 
olites. 
In this paper, we described the screening ofPTPase inhibitors 
and the isolation of RK-682 from Streptomyces sp. 88-682. The 
chemical structure of RK-682 was already described as a HIV-1 
protease inhibitor by other researchers [20]. However, RK-682 
inhibited PTPase at a lower concentration compared with HIV 
protease reported in the paper. RK-682 consists of a tetronic 
acid and a saturated fatty acid moiety. It was known that fatty 
acids showed various non-specific inhibitory activities against 
purified enzymes. RK-682 derivatives which have a part of the 
structure showed only weak inhibitory activity to VHR, but not 
MW(KDa) 
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Fig. 4. The effect ofphosphatase inhibitors on tyrosine phosphorylation n Ball-1 cells. Thirty micrograms of protein were loaded per lane, then stained 
by Coomassie blue (A). Ten micrograms of protein per lane were loaded for Western blotting with anti-phosphotyrosine (B) or anti-phosphothreonine 
(C). Phosphatase inhibitors okadaic acid (5, 10/tM; lanes 2 and 3), vanadate (250, 500/IM; lanes 4 and 5) and RK-682 (40, 80 and 160/tM; lanes 
6, 7 and 8) were added to Ball-1 cells. Lane 1 is a control without inhibitor. 
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Fig. 5. The influence of PTPase inhibitors on cell cycle progression. After Ball-1 cells (1 x 105) were treated with vanadate 80 pM (B) and RK-682 
30 pM (C), DNA content was analyzed by flow cytometry. The cells without treatment were shown in (A). 
at all to CD45 (data not shown). Therefore, the whole structure 
of RK-682 is necessary to recognize and inhibit the protein 
phosphatases. 
Vanadate is a well known and useful inhibitor to investigate 
the role of PTPase in the signal transduction. In this paper, 
we found that noticeable differences between vanadate and 
RK-682. First, RK-682 was more potent inhibitor (approxi- 
mately 20 times stronger) compared with vanadate toward 
VHR and CD45 (Fig. 2). Second, the inhibitory profile of 
RK-682 and vanadate to VHR substrate pNpp are noncompet- 
itive and competitive, respectively (Fig. 3). Third, vanadate 
enhanced the phosphotyrosine level of 60 kDa protein in Ball-1 
cell, whereas RK-682 enhanced that of 110 kDa protein 
(Fig. 4). Finally, these PTPase inhibitors had the different ar- 
rest point on the cell cycle progression of Ball-1 cell (Fig. 5) and 
a mouse tsFT210 cell [21] (data not shown). 
The mammalian cell cycle progression is regulated by cyclin 
dependent kinases (cdks) [2,3,22-24]. At the G2/M transition, 
the activation of the cdc2-cyclin B complex depends on the 
activities of cdc25B [14] and cdc25C [25]. In fact, vanadate 
inhibited the cdc25B in vitro, but RK-682 did not (Fig. 6). The 
GI/S transition requires cdk2 activity [22]. The cdk2-cyclin E 
complex was essential during S-phase for the phosphorylation 
of cdc25A [23]. Cdil (cyclin-dependent kinase interactor) is a 
dual-specificity phosphatase and negatively regulates cdk2 [24]. 
However, the principal which dephosphorylates and activates 
cdk2~zyclin E has not yet been cleared. RK-682 inhibited the 
Table 1 
Purification of RK-682 
Fraction Total 
amount 
[g] 
Activity* 
Total Specific Yield Purification 
[U] [U/g] [~] -fold 
Ethyl acetate xtract 47.3 9500 200 100 1.0 
Silica gel 11.0 9100 830 95 4.2 
Sephadex LH-20 1.1 9000 8200 94 41.5 
HPLC (ODS) 0.17 8000 47000 83 237.0 
The isolation of RK-682 was monitored by means of its inhibitory 
activity towards VHR and the procedure was revealed in section 2.1. 
*One unit is the amount of RK-682 required to inhibit to de- 
phosphorylation activity of GST-VHR (1 pg). 
cell cycle progression at G] phase (Fig. 5C) but not the phos- 
phatase activity of cdc25B (Fig. 6), and the elucidation of this 
observation is a further investigation. 
In this paper, RK-682 was described as a specific inhibitor 
of PTPases and used as a biochemical probe to investigate the 
mammalian cell cycle. The specific inhibitor of PTPase should 
be an useful tool to reveal the importance of protein phosphor- 
ylation and dephosphorylation n various mammalian cells [26]. 
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Fig. 6. Effect of PTPase inhibitors on cdc25B in vitro. Inhibitory activ- 
ity of RK-682 (e) and vanadate (A) against the phosphatase activity of 
cdc25B to pNpp. 
58 T. Hamaguchi et al./FEBS Letters 372 (1995) 54 58 
References 
[1] Sun, H. and Tonks, N.K. (1994) Trends Biochem. Sci. 19, 480-485. 
[2] Murray, A.W. and Kirschner, M.W. (1989) Science 246, 614-621. 
[3] Dunphy, W.G. and Kumagai, A. (1991) Cell 67, 189-196. 
[4] Ishibashi, T., Bottaro, D.E, Chan, A., Miki, T. and Aaronson, 
S.A. (1992) Proc. Natl. Acad. Sci. USA 89, 12170-12174. 
[5] Mustelin, T., Coggeshall, K.M. and Altman, A. (1989) Proc. Natl. 
Acad. Sci. USA 86, 6302-6306. 
[6] Mustelin, T., Morikawa, T.P., Autero, M., Gassmann, M., 
Andersson, L.C., Gahmberg, C.G. and Burn, P. (1992) Eur. J. 
Immunol. 22, 1173-1178. 
[7] Shiroo, M., Goff, L., Biffen, M., Shivnan, E. and Alexander, D. 
(1992) EMBO J. 11, 4887~t897. 
[8] Cahir Mcfarland, E.D., Hurley, T.R., Pingel, J.T., Sefton, B.M., 
Shaw, A. and Thomas, M.L. (1993) Proc. Natl. Acad. Sci. USA 
90, 1402 1406. 
[9] Lin, J., Brown, V.K. and Justement, L.B. (1992) J. Immunol. 149, 
3182 3190. 
[10] Ishihara, H., Martin, B.L., Brautigan, D.L., Karaki, H., Ozaki, 
H., Kato, Y., Fusetani, N., Watabe, S., Hashimoto, K., Uemura, 
D. and Hartshorne, D.J. (1989) Biochem. Biophys. Res. Commun. 
159, 871-877. 
[11] Magae, J., Osada, H., Fujiki, H., Saido, T.C., Suzuki, K., Nagai, 
K., Yamasaki, M. and Isono, K. (1990) Proc. Jap. Acad. 66, Ser 
B, 209-212. 
[12] Morales, EG., Minami, Y., Luong, E., Klausner, R.D. and 
Samelson, L.E. (1990) Proc. Natl. Acad. Sci. USA 87, 9255 9259. 
[13] Imoto, M., Kakeya, H., Sawa, T., Hayashi, C., Hamada, M., 
Takeuchi, T. and Umezawa, K. (1993) J. Antibiot. 46, 1342-1346. 
[14] Honda, R., Ohba, Y., Nagata, A., Okayama, H. and Yasuda, H. 
(1993) FEBS Lett. 318, 331 334. 
[15] Tonks, N.K., Diltz, C.D. and Fischer, E.H. (1988) J. Biol. Chem. 
14, 6731-6737. 
[16] Mustelin, T., Coggeshall, K.M. and Altman, A. (1989) Proc. Natl. 
Acad. Sci. USA 86, 630~6306. 
[17] Stone, R.L. and Dixon, J.E. (1994) J. Biol. Chem. 269, 31323 
31326. 
[18] Zheng, C.F. and Guan, K.L. (1993)J. Biol. Chem. 268, 16116- 
16119. 
[19] Charles, C.H., Sun, H., Lau, L.F. and Tonks, N.K. (1993) Proc. 
Natl. Acad. Sci. USA 90, 5292-5296. 
[20] Roggo, B.E., Petersen, F., Delmendo, R., Jenny, H.-B., Peter, 
H.H. and Roesel, J. (1994) J. Antibiot. 47, 136-142. 
[21] Mineo, C., Murakami, Y., Ishimi, Y., Hanaoka, F. and Yamada, 
M. (1986) Exp. Cell. Res. 167, 53-62. 
[22] Tsai, L.-H., Lees, E., Faha, B., Harlow, E. and Riabowol, K. 
(1993) Oncogene 8, 1593-1602. 
[23] Hoffmann, I., Draetta, G. and Karsenti, E. (1994) EMBO J. 4302- 
4310. 
[24] Gyuris, J., Golemis, E., Chertkov, H. and Brent, R. (1993) Cell 75, 
791-803. 
[25] Hoffmann, I., Clarke, ER., Marcote, M.J., Karsenti, E. and 
Draetta, G. (1993) EMBO J. 12, 53-63. 
[26] Fujii, S., Kato, H., Furuse, H., Ito, K., Osada, H., Hamaguchi, T.
and Kuroda, Y. (1995) Neurosci. Lett. 187, 130 132. 
